Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 2
1983 3
1984 5
1985 30
1986 77
1987 92
1988 130
1989 167
1990 200
1991 182
1992 277
1993 302
1994 344
1995 347
1996 352
1997 329
1998 317
1999 337
2000 322
2001 361
2002 347
2003 319
2004 378
2005 384
2006 352
2007 318
2008 356
2009 364
2010 388
2011 395
2012 425
2013 421
2014 397
2015 455
2016 439
2017 410
2018 355
2019 387
2020 407
2021 422
2022 358
2023 330
2024 132

Text availability

Article attribute

Article type

Publication date

Search Results

11,795 results

Results by year

Filters applied: . Clear all
Page 1
Somatostatin vs. Octreotide for Prevention of Postoperative Pancreatic Fistula The PREFIPS Randomized Clinical Trial A FRENCH 007 - ACHBT Study.
Gaujoux S, Regimbeau JM, Piessen G, Truant S, Foissac F, Barbier L, Buc E, Adham M, Fuks D, Deguelte S, Muscari F, Sulpice L, Vaillant JC, Schwarz L, Sa Cunha A, Muzzolini M, Dousset B, Sauvanet A. Gaujoux S, et al. Ann Surg. 2024 Apr 25. doi: 10.1097/SLA.0000000000006313. Online ahead of print. Ann Surg. 2024. PMID: 38662619
The present study compares clinically significant POPF rates in patients randomized between somatostatin versus octreotide as prophylactic treatment. PATIENTS AND METHODS: Multicentric randomized controlled open study in patient's candidate for pancreaticoduodenectomy (PD) …
The present study compares clinically significant POPF rates in patients randomized between somatostatin versus octreotide as prophyl …
Efficacy of nil per oral, total parenteral nutrition, milrinone and non-suction chest tube drainage-based management for chylothorax following pediatric cardiac surgery.
Rahmath MRK, Bhat AN, Lone RA, Kamal RY. Rahmath MRK, et al. Asian Cardiovasc Thorac Ann. 2024 Apr 24:2184923241249198. doi: 10.1177/02184923241249198. Online ahead of print. Asian Cardiovasc Thorac Ann. 2024. PMID: 38659299
Group-1(35 patients-treated during the years 2011-2015) included those who were managed with low fat diet initially with other standard measures including steroid, octreotide, pleurodesis, lymphangiogram or thoracic duct ligation whenever required.Group-2 (20 patients, tre …
Group-1(35 patients-treated during the years 2011-2015) included those who were managed with low fat diet initially with other standard meas …
Successful medical management of a pituitary macroadenoma with features of resistant acromegaly and hyperprolactinemia using pasireotide.
Baagar KA, Sadiq A, Khan AA, Dabbous Z, Rohani Z. Baagar KA, et al. Qatar Med J. 2024 Mar 14;2024(1):17. doi: 10.5339/qmj.2024.17. eCollection 2024. Qatar Med J. 2024. PMID: 38654814 Free PMC article.
He was treated with cabergoline and later, long-acting release (LAR) octreotide. Prolactin levels were reduced with cabergoline, but IGF-1 levels did not respond to octreotide, and it was discontinued. ...CONCLUSIONS: The case suggests that pasireotide can provide m …
He was treated with cabergoline and later, long-acting release (LAR) octreotide. Prolactin levels were reduced with cabergoline, but …
Investigation of Basolateral Targeting Micelles for Drug Delivery Applications in Polycystic Kidney Disease.
Huang Y, Osouli A, Pham J, Mancino V, O'Grady C, Khan T, Chaudhuri B, Pastor-Soler NM, Hallows KR, Chung EJ. Huang Y, et al. Biomacromolecules. 2024 Apr 23. doi: 10.1021/acs.biomac.3c01397. Online ahead of print. Biomacromolecules. 2024. PMID: 38652072
To address this, we identified four drug candidates from ADPKD clinical trials, bardoxolone methyl (Bar), octreotide (Oct), salsalate (Sal), and pravastatin (Pra), and incorporated them into peptide amphiphile micelles containing the RGD peptide (GRGDSP), which binds to th …
To address this, we identified four drug candidates from ADPKD clinical trials, bardoxolone methyl (Bar), octreotide (Oct), salsalate …
Investigational drugs for the Treatment of Acromegaly: new agents to transform therapy.
Pirchio R, Auriemma RS, Vergura A, Pivonello R, Colao A. Pirchio R, et al. Expert Opin Investig Drugs. 2024 Apr 23. doi: 10.1080/13543784.2024.2343056. Online ahead of print. Expert Opin Investig Drugs. 2024. PMID: 38651260 Review.
AREAS COVERED: The aim of current review is to provide a detailed update about investigational drugs for acromegaly treatment currently under investigation as paltusotine, ONO-5788, AP102, GT-02037, ISIS 766,720, CAM2024, Lanreotide PRF, DP1038, MTD201, solid dose injection of …
AREAS COVERED: The aim of current review is to provide a detailed update about investigational drugs for acromegaly treatment currently unde …
[Current developments in the treatment of neuroendocrine tumors].
Kiesewetter-Wiederkehr B, Melhorn P, Scheuba C, Raderer M. Kiesewetter-Wiederkehr B, et al. Radiologie (Heidelb). 2024 Apr 22. doi: 10.1007/s00117-024-01303-2. Online ahead of print. Radiologie (Heidelb). 2024. PMID: 38649498 Review. German.
Major advances have been made in drug therapy, with somatostatin analogs (octreotide and lanreotide), an mTOR inhibitor (everolimus), and a tyrosine kinase inhibitor (sunitinib) being widely used. ...
Major advances have been made in drug therapy, with somatostatin analogs (octreotide and lanreotide), an mTOR inhibitor (everolimus), …
A retrospective study of paraganglioma of the urinary bladder and literature review.
Zhao Y, Zhang Z, Wang S, Wen J, Wang D, Ji Z, Zhang Y, Li H. Zhao Y, et al. Front Surg. 2024 Apr 5;11:1348737. doi: 10.3389/fsurg.2024.1348737. eCollection 2024. Front Surg. 2024. PMID: 38645508 Free PMC article.
Normetanephrine in seven patients was increased. Six of 18 metaiodobenzylguanidine and 8 of 22 octreotide scans were positive. In total, 15 cases underwent laparoscopic partial cystectomy and 14 underwent transurethral resection of bladder tumor. ...
Normetanephrine in seven patients was increased. Six of 18 metaiodobenzylguanidine and 8 of 22 octreotide scans were positive. In tot …
Challenging diagnosis of resistance to thyroid hormone in a patient with COVID-19, pituitary microadenoma and unusual response to octreotide long-acting release test.
Petolicchio C, Brasili S, Gay S, Cocchiara F, Campi I, Persani L, Vera L, Ferone D, Gatto F. Petolicchio C, et al. Endocrinol Diabetes Metab Case Rep. 2024 Apr 17;2024(2):23-0146. doi: 10.1530/EDM-23-0146. Print 2024 Apr 1. Endocrinol Diabetes Metab Case Rep. 2024. PMID: 38642577 Free article.
Due to atrial fibrillation, the execution of the T3 test was contraindicated. The octreotide long-acting release (LAR) test showed an initial reduction of free thyroid hormones levels at first administration, which was consistent with the presence of a TSH-secreting pituit …
Due to atrial fibrillation, the execution of the T3 test was contraindicated. The octreotide long-acting release (LAR) test showed an …
Management of hepatorenal syndrome and associated outcomes: a systematic reviews.
Roozbeh J, Ezzatzadegan Jahromi S, Rezazadeh MH, Hamidianjahromi A, Malekmakan L. Roozbeh J, et al. BMJ Open Gastroenterol. 2024 Apr 17;11(1):e001319. doi: 10.1136/bmjgast-2023-001319. BMJ Open Gastroenterol. 2024. PMID: 38631807 Free PMC article. Review.
Of which 24 articles were conducted on terlipressin versus placebo or other treatments (midodrine/octreotide, norepinephrine, etc) that showed the higher rate of HRS reversal was detected for terlipressin in 17 studies (10 of them were significant), 2 studies achieved an i …
Of which 24 articles were conducted on terlipressin versus placebo or other treatments (midodrine/octreotide, norepinephrine, etc) th …
Al(18)F-NOTA-Octreotide outperforms (18)F-FDG in identifying rare renal metastases from pancreatic neuroendocrine tumor.
Diao W, Ye Z, Kou Y, Cheng Z. Diao W, et al. Hell J Nucl Med. 2024 Apr 18:s002449912708. doi: 10.1967/s002449912708. Online ahead of print. Hell J Nucl Med. 2024. PMID: 38629821
Subsequently, a novel somatostatin receptor imaging agent, Al(18)F-NOTA-octreotide ((18)F-OC), was performed to further investigate the source of metastatic lesions and to stage the tumor. ...
Subsequently, a novel somatostatin receptor imaging agent, Al(18)F-NOTA-octreotide ((18)F-OC), was performed to further investigate t …
11,795 results
You have reached the last available page of results. Please see the User Guide for more information.